



TRANSLATING LEADING SCIENCE INTO THE CLINIC



Centers for Therapeutic Innovation



ABOUT CTI

THE CENTERS FOR THERAPEUTIC INNOVATION (CTI) IS A PIONEERING RESEARCH AND DEVELOPMENT NETWORK INITIATED BY PHARMA THAT USES A COLLABORATIVE MODEL TO BRING GREAT IDEAS TO FRUITION. PART OF PFIZER, WE ARE AN ENTREPRENEURIAL GROUP THAT PARTNERS WITH LEADING ACADEMIC MEDICAL CENTERS AND DISEASE FOUNDATIONS WITH THE AIM OF TRANSLATING PROMISING SCIENCE INTO CLINICAL CANDIDATES.


Our work is based on authentic collaboration, reflected in shared decision making and aligned incentives. We are committed to bringing together cutting-edge academic and industry resources to develop medicines faster and more efficiently.

With locations in Massachusetts, New York and California, our facilities are conveniently located on or near academic campuses, allowing our partners to work closely with Pfizer scientists to translate research ideas into clinical applications, with the ultimate goal of moving a therapeutic hypothesis into clinical trials.

"CTI IS REWIRING THE R&D ECOSYSTEM TO OFFER NEW, TARGETED THERAPIES TO PATIENTS LIVING WITH DISEASE."

- DR. ANTHONY COYLE
Centers for Therapeutic Innovation

CTI'S MODEL



WE ADHERE TO THREE CORE PRINCIPLES, WITH THE END GOAL OF BRINGING NEW INNOVATIONS TO PATIENTS IN NEED.

RESULTS-DRIVEN	ENTREPRENEURIAL	COLLABORATIVE
<p>CTI is results driven. Research teams incorporate scientific milestones into their project plans to allow for clear and swift decision making. Additionally, each project is overseen by a joint steering committee to evaluate the success of the program and monitor progress toward milestones.</p>	<p>CTI embraces an entrepreneurial work environment so that its partners and employees can address R&D challenges through a unique operating model that champions innovation.</p>	<p>CTI is committed to collaboration. We are reinventing partnerships between academia, disease foundations and pharma.</p>



PARTNER WITH US

We are a premier partner of choice for leading academic medical centers and disease foundations to translate promising science into clinical candidates. With the backing of Pfizer resources, including unprecedented access to our world-class antibody libraries and technologies, we provide our partners with the opportunity to further develop and research a promising therapeutic or hypothesis.

“PARTNERING WITH CTI HAS GIVEN ME THE OPPORTUNITY TO LEVERAGE PFIZER’S RESOURCES TO ACCELERATE THE RESEARCH IN MY LAB. IT’S A GREAT PARTNERSHIP MODEL.”

- DR. HAROLD DVORAK
Beth Israel Deaconess Medical Center

ACADEMIC MEDICAL CENTERS

AT CTI, WE OFFER FUNDING AND RESOURCES TO PRINCIPAL INVESTIGATORS AND POST-DOCS AT ACADEMIC MEDICAL CENTERS TO CONTINUE DEVELOPMENT AND RESEARCH ON A PROMISING THERAPEUTIC OR HYPOTHESIS.

In the large-molecule arena, our unique collaboration model allows us to jointly discover and develop therapeutic candidates from early research through Proof-of-Mechanism (PoM) in humans. Our partners are given unprecedented access to Pfizer's world-class antibody library and technologies, and offered flexibility to conduct agile research. In the small-molecule arena, our partners are presented with the opportunity to access Pfizer's small-molecule libraries and draw upon the company's extensive chemistry expertise.

Throughout the year, we issue a call for proposals to academic medical centers for projects. Each project is overseen by a joint steering committee (JSC) comprised equally of Pfizer scientists and partner-appointed academics to evaluate the success of the program and whether milestones are appropriately met. Incentives are aligned with joint intellectual property and ownership, broad rights to publication, and milestone payments and royalties for successful programs.

In October 2010, we announced our first partnership with the University of California, San Francisco; today, we have partnered with more than 20 leading academic medical centers across the U.S., and we have reviewed more than 500 project proposals.



FOUNDATIONS

PATIENT ADVOCACY FOUNDATIONS, WITH THEIR RICH KNOWLEDGE OF A PARTICULAR DISEASE, EXTENSIVE EXPERIENCE FUNDING RESEARCH IN THEIR FIELDS, AND ACCESS TO EXPERTS, INFORMATION AND PATIENTS CAN SIGNIFICANTLY ENHANCE THE DRUG DISCOVERY PROCESS.

At CTI, we provide foundations with an opportunity to leverage their resources with those of big pharma to target therapeutics in a specific disease area.

Our first foundation partnership was signed with the Alliance for Lupus Research (ALR) and announced in November 2012. CTI and its foundation partners share equal decision-making rights, including selecting projects to incorporate into CTI's pipeline and evaluation of project progress.

CTI's goal and that of disease foundations is the same – to provide new, targeted therapies to patients living with disease. Our hope is that by combining our resources we can speed the creation of life-saving treatments for patients who need them.

"THE ALLIANCE FOR LUPUS RESEARCH'S GOAL IS SIMPLE — TO FUND RESEARCH FOCUSED ON THE CAUSE, TREATMENT AND CURE OF LUPUS. WITH CTI, THE ALR LEVERAGES ITS RESOURCES WITH THOSE OF PFIZER TO ACHIEVE THIS GOAL MORE QUICKLY AND EFFECTIVELY."

- KENNETH FARBER
Alliance for Lupus Research

CO-LOCATED SITES

Our CTI sites were strategically chosen to capitalize on dynamic research communities throughout the U.S. Close proximity of the CTI labs to academic labs allows for in-person dialogue and collaborative problem solving, as well as facilitates the exchange of approved reagents and tools.

CTI-BOSTON



Located in the heart of the Longwood Medical area, our Boston location is adjacent to premier research centers, including the Partners network, Beth Israel Deaconess Medical Center and Harvard Medical School.

CTI-CALIFORNIA



We have two sites in California – one in San Francisco and one in San Diego. Our San Francisco lab is in the Mission Bay neighborhood, across the street from the University of California, San Francisco campus. Our San Diego laboratory helps to foster collaboration with partners from the University of California, San Diego and Sanford-Burnham Medical Research Institute.

CTI-NEW YORK



Our New York location is on the East Side of Manhattan with close proximity to NYU Medical Center, as well as the Mount Sinai School of Medicine, Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, among others.



Centers for Therapeutic Innovation

Detailed information about CTI is online at www.PfizerCTI.com